Bio
Julie is the SVP, Clinical Development and Drug Safety/Pharmacovigilance at Travere Therapeutics. She has extensive experience in rare disease drug development across all the phases of clinical studies. Prior to joining Travere, she has held leadership positions at Amgen, Genzyme, Ultragenyx, and Sanofi.
"HARMONY Study: Phase 3 Clinical Trial for Pegtibatinase"
Inform the audience of the pegtibatinase clinical program including the design of HARMONY, a pivotal trial for HCU.
